Drug | Target | Biomarkers | Effects | Route/Dose |
---|---|---|---|---|
Omalizumab | IgE | Ag-specific IgE Better responses with higher FeNO and blood eosinophils >300 cells/ uL | Decreased asthma exacerbations | 150–375 mg SC q2-q4wks; frequency based on IgE and body weight |
Mepolizumab | IL-5 | Blood eosinophil count >150 cells/uL at initiation or 300 cells/uL in past year | Decreased asthma exacerbations; Improvement in FEV1 | 100Â mg SC q4wk. |
Reslizumab | IL-5 | Blood eosinophil count >400 cells/uL | Decreased asthma exacerbations; Improvement in FEV1 | 3Â mg/kg IV q4wks |
Benralizumab | IL-5Rα | Blood eosinophil count >300 cells/ uL | Decreased asthma exacerbations; Improvement in FEV1. | 30 mg SC q4wks ×3 then q8wks |
Tralokinumab | IL-13 | Elevated blood periostin and DDP-4 | Improvement in FEV1 | Not Defined |
Dupilumab | IL-4Rα | Better responses with blood eosinophil count >300 cells/ uL | Decreased asthma exacerbations; Improvement in FEV1 | 200 or 300 mg SC q2wks; administered at home |